Saura‘s lab at the Universitat Autònoma de Barcelona investigates the cellular and molecular mechanisms involved in the pathogenesis of cognitive disorders, particularly in Alzheimer’s disease.

Our research efforts are currently focused on understanding how brain functions during memory processing and the cellular and molecular mechanisms involved in brain dysfunction, memory loss and neurodegeneration in age-related cognitive disorders. Our lab combines molecular approaches and cutting-edge genomic, transcriptomic and proteomic methodologies to better understand the molecular pathways causing neuronal dysfunction, memory loss and neurodegeneration in Alzheimer’s disease.

Dr. Carles Saura’s lab investigates the transcriptional pathways that regulate synaptic plasticity underlying cognition and memory, which allows a better understanding of the mechanisms mediating gene expression changes causing synaptic dysfunction and memory loss in cognitive disorders, especially in Alzheimer’s disease.

We use pioneering approaches to generate novel transgenic and knockout mouse models of neurodegeneration that are used for testing new therapeutic strategies (pharmacological, gene therapy, cognitive stimulation…) for future treatment of age-related dementia disorders. Our research projects provide knowledge of novel molecular targets and therapeutic strategies for early treatment of Alzheimer’s disease and related neurological disorders.

Our investigations focus in three main topics:

1. Cellular mechanisms in Alzheimer’s  disease.

2. Novel research tools and models of neurodegeneration.

3. Therapies for Alzheimer’s  disease and cognitive disorders.

UAB research project to Saura’s lab to find cures for Alzheimer’s disease granted by the BrightFocus Foundation. June 29, 2022. Read more

New review ¨Revealing cell vulnerability in Alzheimer’s disease by single-cell transcriptomics¨ published in Seminars Cell Dev Biology. June, 2022. Read more

Editorial in Frontiers Molecular Neuroscience¨Bidirectional communication between synapses and nucleus in brain physiology and disease¨. May 6, 2022. Read more

A new study
from the lab reveals a presenilin-dependent loss of function mechanism in tau pathology during neurodegeneration. The study is published in Acta Neuropath Comms. Sept 30, 2021. Read more

Our collaborative study with Dr. R. Andero’s lab (INc-UAB) published in Nature Communications demonstrates for the first time sex-differences in fear memory via Tac2 and Akt/GSK3β/β-catenin pathways. See article: Nat Comm. May 3, 2021. Read news

Published two new reviews in Cells and Frontiers in Neuroscience on the role of non-muscle myosins in brain development and degeneration (Cells) and Tissue clearing methods for the study of brain pathology in neurodegeneration (Frontiers in Neuroscience). October 1, 2020. Read more

Two new studies on mechanisms of AMPAR-dependent synaptic plasticity and microglial NMDAR signaling   featured in eNeuro and Cells. March 23/April 26, 2020. Read more

eLife manuscript published. Our new study published in eLife demonstrates a role of the Alzheimer’s disease-linked gene Presenilin-1/g-secretase in axon growth by regulating EphA3/myosin IIA signaling. October 30, 2019. Read more

A new biomarker in blood in early Alzheimer’s disease. Our new discovery published in the journal Alzheimer’s Research and Therapy identifies a new molecular signature of miRNAs in blood at early Alzheimer’s disease stages. May 17, 2019. Read more

The Saura lab is actively exploring and developing research on the following topics: